
|Videos|September 13, 2022
Cate Lockhart Presents on the Uptake of Biosimilars at PBMI 2022
Author(s)Briana Contreras
Cate Lockhart, MS, PharmD, PhD, Executive Director at the Biologics and Biosimilars Collective Intelligence Consortium covers her presentation "New mAbs on the Block: A Rocking Research Update on Biosimilar Uptake and Benefit Design" which she delivered at this year's PBMI national conference.
Advertisement
Cate Lockhart, MS, PharmD, PhD, Executive Director at the Biologics and Biosimilars Collective Intelligence Consortium covers her presentation "New mAbs on the Block: A Rocking Research Update on Biosimilar Uptake and Benefit Design" which she delivered at this year's PBMI national conference.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients
2
Zepbound linked to lower healthcare costs in older adults with obesity
3
FDA approves brepocitinib for rare skin disease
4
Employer health care costs projected to rise 9.5% in 2027, report finds
5













